摘要
目的 探索真实世界中较高危骨髓增生异常综合征(MDS)患者应用补肾解毒化瘀法治疗的血常规指标、骨髓指标表现及疗效分析。方法 选择2017年9月-2022年9月中国中医科学院西苑医院血液科病房162例较高危MDS患者的临床资料,对其一般资料、血常规指标、骨髓指标进行分析。结果 162例较高危MDS患者应用补肾解毒化瘀法为主的中西医结合治疗的总体有效率为48.8%。当较高危MDS患者年龄<70岁、应用补肾解毒化瘀法联合化疗治疗时,更易获得疗效(P<0.05)。补肾解毒化瘀法治疗后,较高危MDS患者血小板(PLT)水平较治疗前明显升高(P<0.05),且无效组的PLT水平提高更为显著(P<0.05)。治疗后有效组患者血红蛋白(HGB)水平明显升高(P<0.05)。治疗后,较高危MDS患者的骨髓粒系占比、巨核细胞数及淋巴细胞比例均较治疗前明显升高(P<0.05)。结论 含砷中药复方为主的补肾解毒化瘀法治疗较高危MDS,能够提高患者的HGB含量、PLT水平,提高患者骨髓粒系占比、巨核细胞数及淋巴细胞比例,且对于降低骨髓原始细胞比例,即去甲基化方面也发挥一定作用。
Objective To explore the performance of routine blood test parameters,bone marrow parameters and the risk factors of leukemia conversion in higher-risk patients with myelodysplastic syndrome(MDS)treated with Bushen Jiedu Huayu Method in the real world.Methods The clinical data of 162 patients with higher-risk MDS who were admitted to the Department of Hematology,Xiyuan Hospital,China Academy of Chinese Medical Sciences from September 2017 to September 2022 were collected,and their clinical data,blood routine parameters,and bone marrow parameters were analyzed.Results A total of 162 higher-risk MDS patients were included,and the overall effective rate of the combination of traditional Chinese and Western medicine treatment,mainly using Bushen Jiedu Huayu Method being 48.8%.Patients with higher-risk MDS who were younger than 70 years old were more likely to obtain curative effect when treated with Bushen Jiedu Huayu Method combined with chemotherapy(P<0.05).After treatment with Bushen Jiedu Huayu Method,PLT levels in higher-risk MDS patients were significantly higher than those before treatment(P<0.05),and PLT levels in the ineffective group increased more significantly(P<0.05).After treatment,the HGB level in the effective group significantly increased(P<0.05).After treatment,the proportion of bone marrow granulocytes,megakaryocytes and lymphocytes in higher-risk MDS patients were significantly higher than those before treatment(P<0.05).Conclusion Bushen Jiedu Huayu Method,mainly using arsenic containing TCM compound,can treat higher-risk MDS.It can increase the HGB content and PLT level of patients,increase the proportion of bone marrow granulocytes,megakaryocytes and lymphocytes,and also play a certain role in reducing the proportion of bone marrow primitive cells,namely demethylation.
作者
刘健
李芮
杨秀鹏
王洪志
许勇钢
陈卓
王德秀
肖海燕
唐旭东
LIU Jian;LI Rui;YANG Xiupeng;WANG Hongzhi;XU Yonggang;CHEN Zhuo;WANG Dexiu;XIAO Haiyan;TANG Xudong(Graduate School of Beijing University of Chinese Medicine,Beijing 100029,China;Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China)
出处
《中国中医药信息杂志》
CAS
CSCD
2024年第9期145-151,共7页
Chinese Journal of Information on Traditional Chinese Medicine
基金
国家自然科学基金面上项目(82074258、82274502)
第二批北京市研究型病房示范建设项目(BCRW202108)
中国中医科学院科技创新工程重大攻关项目(CI2021A01701)。
